Plain-English translation of NCT06121700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating stomach cancer that has spread to a few other places in the body. The study combines radiation therapy, , and anti-PD-1 immunotherapy (a medication that helps your immune system fight cancer) followed by surgery to remove the cancer. Researchers want to see if this multi-step treatment plan can help people with this type of cancer live longer and stay healthy.
Stomach cancer that has spread is very difficult to treat, and standard treatments don't always work well for everyone. This trial exists to find out whether adding immunotherapy to radiation and —and then removing the cancer with surgery—might give patients a better chance of survival and longer-term benefit.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive short-course radiation therapy focused on your primary tumor and any spots where cancer has spread, combined with and anti-PD-1 immunotherapy given through the bloodstream. After this initial treatment, you will undergo surgery to remove the primary cancer and metastatic lesions if possible; if surgery is not feasible, you may receive alternative ablation therapies. Following surgery, you will continue on immunotherapy for up to one year after your operation, along with additional as determined by your doctor. You will have regular follow-up visits and imaging scans to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China